<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04818918</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0123456</org_study_id>
    <nct_id>NCT04818918</nct_id>
  </id_info>
  <brief_title>Coronary Flow and Myocardial Viability: the FloVITA Study</brief_title>
  <acronym>FloVita</acronym>
  <official_title>Study of the Relationship Between Coronary Flow and Myocardial Viability: the Single-centre, Observational, Prospective FloVITA Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of fractional flow reserve (FFR) is a key method for assessing ischemia with a&#xD;
      view to guiding revascularization strategy following acute coronary syndrome. A stenosis that&#xD;
      appears to be severe by angiography may cause limited ischemia (with an FFR value &gt;0.80) due&#xD;
      to the incapacity of the necrotic zone to achieve physiological hyperemia, i.e. maximal&#xD;
      coronary flow. Recently, it has been demonstrated that absolute coronary flow, and micro- and&#xD;
      macrovascular resistance, as measured by a thermodilution technique, using the Rayflow&#xD;
      microcatheter (Hexacath) are strongly associated with myocardial mass. In extensive necrosis,&#xD;
      there is a loss of myocardial mass, and these tools could be of potential interest in&#xD;
      measuring myocardial viability, which reflects the extent of remaining viable myocardial&#xD;
      mass.&#xD;
&#xD;
      Therefore, this study aims to investigate the relationship between both absolute coronary&#xD;
      flow and microvascular resistance, and myocardial viability assessed by MRI.&#xD;
&#xD;
      In a prospective, single-centre, interventional study, we will compare absolute coronary flow&#xD;
      and microvascular resistance in the left anterior descending artery, in patients with and&#xD;
      without a history of ST segment elevation MI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 19, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 20, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary flow (mL/min) in the LAD</measure>
    <time_frame>At the end of the angiography procedure</time_frame>
    <description>Measurement of coronary flow in mL/min in the left anterior descending artery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microvascular resistance</measure>
    <time_frame>At the end of the angiography procedure</time_frame>
    <description>Measurement of microvascular resistance in the LAD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial necrosis</measure>
    <time_frame>Cardiac MRI to be performed 7 to 30 days after index angiography procedure</time_frame>
    <description>Extent of myocardial necrosis on cardiac MRI (number of segments)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>STEMI group</arm_group_label>
    <description>Patients with anterior ST segment MI treated with percutaneous coronary intervention of the left anterior descending artery, at least 7 days prior to inclusion, and scheduled for new angiography to evaluate FFR of a lesion other than the infarct-related artery.&#xD;
Absolute coronary flow and microvascular resistance will be measured in the LAD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Patients undergoing non-urgent coronary angiography for stable angina or silent ischemia, with measure of FFR on one or more vessels (intermediate lesions &lt;90% without proven ischemia). Absence of any signfiicant lesion on the left anterior descending artery (as evaluated by angiography or FFR value &gt;0.8).&#xD;
Absolute coronary flow and microvascular resistance will be measured in the LAD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Absolute coronary flow measurement</intervention_name>
    <description>Absolute coronary flow will be measured.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>STEMI group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microvascular resistance measurement</intervention_name>
    <description>Microvascular resistance will be measured.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>STEMI group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiac MRI</intervention_name>
    <description>Cardiac MRI will be performed to evaluate myocardial viability.</description>
    <arm_group_label>STEMI group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with recent (&gt;=7 days) ST segment elevation MI for the intervention group, and&#xD;
        patients with stable angina or silent ischemia for the control group.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion criteria for the STEMI group:&#xD;
&#xD;
               -  ST segment elevation MI â‰¥7 days treated by angioplasty of the left anterior&#xD;
                  descending (LAD) artery&#xD;
&#xD;
               -  Scheduled to undergo angiography for fractional flow reserve (FFR) assessment of&#xD;
                  a lesion other than the infarct-related artery.&#xD;
&#xD;
          -  Inclusion criteria for the control group:&#xD;
&#xD;
               -  patients undergoing non-urgent coronary angiography for stable angina or silent&#xD;
                  ischemia&#xD;
&#xD;
               -  with measure of the FFR on one or more vessels (intermediate lesion &lt;90% without&#xD;
                  proven ischemia)&#xD;
&#xD;
          -  absence of any significant lesion on the LAD (as assessed by angiography or FFR&gt;0.8)&#xD;
&#xD;
          -  Inclusion criteria for both groups:&#xD;
&#xD;
               -  Written informed consent&#xD;
&#xD;
               -  Affiliation to a social security regimen (or beneficiary thereof).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Target vessel (LAD) not permeable.&#xD;
&#xD;
          -  FFR &lt;0.8 in the LAD&#xD;
&#xD;
          -  Coronary spasm&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt;0.50 or a history of anterior MI in patients in&#xD;
             the control group&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy&#xD;
&#xD;
          -  Severe valvular heart disease&#xD;
&#xD;
          -  History of coronary artery bypass graft&#xD;
&#xD;
          -  Patients with limited legal capacity or patients under guardianship/tutorship&#xD;
&#xD;
          -  Patients with anticipated poor compliance as assessed by the investigator&#xD;
&#xD;
          -  Patients not affiliated to any social security regime.&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  Subjects within the exclusion period of another clinical trial as noted in the&#xD;
             national registry of research volunteers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Meneveau, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Besancon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benoit Guillon, MD</last_name>
    <phone>33381668185</phone>
    <email>benoit.guillon@univ-fcomte.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Besancon</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoit Guillont, MD</last_name>
      <email>benoit.guillon@univ-fcomte.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>microvascular resistance</keyword>
  <keyword>fractional flow reserve</keyword>
  <keyword>myocardial viability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

